Crystalvue Medical (6527) is a TW-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of NT
.7B, trading at NT$68.90 on the TWO. This SniperIQ fundamentals page covers Crystalvue Medical's valuation (P/E 12.1x, P/B 1.8x), profitability (net margin 15.8%), revenue (NT$949M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
.7B
P/E (TTM)12.1x
Net Margin15.8%
Revenue (FY25)NT$949M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Crystalvue Medical's market cap?
Crystalvue Medical (6527) has a market capitalization of approximately NT
.7B, trading at NT$68.90 on the TWO. Market cap moves with the live share price.
What is Crystalvue Medical's P/E ratio?
Crystalvue Medical's trailing twelve-month P/E ratio is 12.1x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Crystalvue Medical?
Crystalvue Medical runs a net profit margin of 15.8%, a gross margin of 35.6%, and an operating margin of 19.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Crystalvue Medical generate?
Crystalvue Medical reported revenue of NT$949M for fiscal year 2025, with net income of NT
47M and earnings per share (EPS) of 5.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Crystalvue Medical pay a dividend?
Crystalvue Medical offers a trailing dividend yield of about 4.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Crystalvue Medical financially healthy?
Crystalvue Medical carries a debt-to-equity ratio of 0.01x and a current ratio of 1.75x, with a market beta of 0.67. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Crystalvue Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Crystalvue Medical (6527) the key facts are: market cap NT
.7B, P/E 12.1x, revenue NT$949M, 52-week range 66.3-90.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Crystalvue Medical's full fundamentals live
Get Crystalvue Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.